View ValuationJacobio Pharmaceuticals Group 향후 성장Future 기준 점검 1/6Jacobio Pharmaceuticals Group의 수익이 증가할 것으로 예상됨입니다.핵심 정보n/a이익 성장률n/aEPS 성장률Biotechs 이익 성장22.8%매출 성장률17.7%향후 자기자본이익률3.20%애널리스트 커버리지Low마지막 업데이트12 Mar 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesBoard Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Bai Lu was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Mar 11Jacobio Pharmaceuticals Group Co., Ltd., Annual General Meeting, Jun 05, 2026Jacobio Pharmaceuticals Group Co., Ltd., Annual General Meeting, Jun 05, 2026.공시 • Feb 26Jacobio Pharmaceuticals Group Co., Ltd. to Report Fiscal Year 2025 Results on Mar 10, 2026Jacobio Pharmaceuticals Group Co., Ltd. announced that they will report fiscal year 2025 results on Mar 10, 2026공시 • Oct 24Jacobio Pharma Presents Pre-Clinical Data of Pan-KRAS Inhibitor (JAB-23E73) at AACR-NCI-EORTC International ConferenceJacobio Pharma announced that it presented the pre-clinical data of its internally discovered pan-KRAS inhibitor JAB-23E73 in a poster presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The pre-clinical results demonstrated that JAB-23E73 is a highly potent pan-KRAS (ON/OFF) inhibitor with strong selectivity that spares HRAS and NRAS inhibition. The compound exhibits superior antitumor activity across multiple cancer types harboring different KRAS driver mutations or amplification. In KRAS-driven mouse tumor models, JAB-23E73 induced tumor regression without causing significant body weight loss, indicating good tolerability and a wide therapeutic window. The compound also showed a favorable pharmacokinetic profile for oral administration and exhibited plasma drug concentration-dependent intratumoral p-ERK inhibition. Phase I clinical trials of JAB-23E73 are currently ongoing in both China and the United States for patients with advanced solid tumors harboring KRAS gene alterations.공시 • Aug 19Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025Jacobio Pharmaceuticals Group Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025공시 • Jul 15Jacobio Pharmaceuticals Group Co., Ltd. (SEHK:1167) commences an Equity Buyback for 78,873,528 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2025.Jacobio Pharmaceuticals Group Co., Ltd. (SEHK:1167) commences share repurchases on July 15, 2025, under the program mandated by the shareholders in the Annual General Meeting held on June 10, 2025. As per the mandate, the company is authorized to repurchase up to 78,873,528 shares, representing 10% of its issued share capital. The repurchases will lead to an enhancement of the net asset value per share and/or earnings per share for the company. The repurchases will be made out of the funds legally available for such purpose in accordance with the Articles of Association and the applicable laws of the Cayman Islands and the Listing Rules. The company may cancel such repurchased shares or hold them as treasury shares on or after the Rule Amendment Effective Date. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual General Meeting is required to be held or the date on which the authority is varied or revoked in a General Meeting. As of June 10, 2025, the company has 791,755,080 shares in issue. On July 14, 2025, the company announces a share repurchase program. Under the program, the company will repurchase up to HKD 100 million worth of its shares. The repurchase price of each share shall be no more than 5% higher than the average closing market price for the shares over the five trading days immediately preceding each repurchase. The company intends to fund the program from its own financial resources.공시 • Jul 03Jacobio Pharma Submits Phase I/II Investigational New Drug Application for its Bet Inhibitor JAB-8263 for the Treatment of Autoimmune Diseases to the Center for Drug Evaluation in ChinaJacobio Pharma announced that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibitor JAB-8263 for the treatment of autoimmune diseases to the Center for Drug Evaluation (CDE) in China and has been accepted. According to new regulatory guidelines, the review of JAB-8263's IND application is expected to be completed within 30 working days. Previously, Jacobio has completed phase I clinical trials of JAB-8263 for solid tumor and hematological malignancies in both China and the United States. Data presented at the 2024 American Society of Hematology (ASH) Annual Meeting showed that JAB-8263 demonstrated good tolerability.공시 • Jul 02Jacobio Completes the First Patient Dage in the Phase I/IIa Clinical Trial of Pan-KRAS Inhibitor JAB-23E73 in U.SThe board of directors of JACOBIO PHARMACEUTICALS Group CO., LTD. announced that the Company has completed the first patient dosage in the phase I/IIa clinical trial of its in-house developed pan-KRAS inhibitor JAB-23E73 in U.S. In parallel, the dose-escalation study in China is progressing as planned. KRAS mutations represent one of the most common oncogenic alterations in tumors, occurring in approximately 23%-25% of cancer patients. The mutation frequency is particularly high in pancreatic cancer (90%), colorectal cancer (40%), and non-small cell lung cancer (30%). An estimated 2.7 million newly diagnosed cancer patients worldwide are found to have tumor with KRAS mutations, underscoring the significant unmet need and the potential benefit of pan-KRAS inhibitors for this patient population. JAB-23E73 demonstrates high selectivity for KRAS, effectively inhibiting both the active ("On") and inactive ("Off") states of KRAS, with no inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73 has shown a favorable pharmacokinetic profile and promising anti-tumor activity in preclinical models.공시 • Mar 20+ 1 more updateJacobio Pharmaceuticals Group Co., Ltd. Announces Board and Composition of the Nomination Committee ChangesThe Board of Jacobio Pharmaceuticals Group Co., Ltd. announced that, Ms. Yunyan HU, an executive Director, has been appointed as a member of the Nomination Committee with effect from March 19, 2025 upon the recommendation of the Nomination Committee. Dr. Te-li CHEN, a non-executive Director, has ceased to be a member of the Nomination Committee with effect from March 19, 2025. Following the above changes, the Nomination Committee comprises Dr. Yinxiang WANG as the chairman, and Ms. Yunyan HU, Dr. Ruilin SONG, Dr. Ge WU and Dr. Bai LU as members.공시 • Mar 07Jacobio Pharmaceuticals Group Co., Ltd. to Report Fiscal Year 2024 Results on Mar 19, 2025Jacobio Pharmaceuticals Group Co., Ltd. announced that they will report fiscal year 2024 results on Mar 19, 2025공시 • Jan 07Jacobio Pharma Announces the Registrational Clinical Data of Glecirasib Was Published in Nature MedicineJacobio Pharma announced that the data from a registrational clinical trial of its independently developed KRAS G12C inhibitor glecirasib has been published in Nature Medicine (impact factor 58.7). In the article, Jaocbio disclosed, for the first time, the complete dataset of glecirasib in KRAS G12C mutant non-small cell lung cancer patients in the second line or above setting. The pivotal phase II trial of glecirasib monotherapy demonstrated impressive efficacy, including the confirmed objective response rate of 47.9% (56/117), a median progression-free survival of 8.2 months, and a median overall survival of 13.6 months. Glecirasib has a manageable safety profile. Gleciasib has a favorable gastrointestinal safety profile compared with other KRAS G12C inhibitors. The new drug application of glecirasib is currently under evaluation by the Center for Drug Evaluation of the National Medical Products Administration of China, and has been granted Priority Review Designation.공시 • Dec 09Jacobio Pharma Presents preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASHJacobio Pharmaceuticals Group Co., Ltd. presented preliminary Phase I data of BET inhibitor JAB-8263 to treat myelofibrosis (MF) at the 2024 ASH (American Society of Hematology) Annual Meeting in San Diego, California. The data showed that JAB-8263 was well tolerated with Recommended Phase 2 Dose (RP2D) being 0.3mg QD. The preliminary efficacy data for JAB-8263 monotherapy in MF are promising, as most patients demonstrated spleen volume reduction (SVR) and total symptom score (TSS) reduction. As of the data cutoff date of October 17, 2024, 16 patients with intermediate-/high-risk MF have been enrolled, and 13 patients have undergone at least one post-treatment efficacy assessment. All patients showed a mean SVR-19.95% at week 24 and -26.16% at best response. Two patients achieved =35% SVR, and an SVR of -34.9% was observed in one patient. Six of ten (60%) patients experienced a =50% reduction in TSS at week 24. The best response of SVR in 2 of 8 patients (JAK inhibitors-treated) was -41.2% and -34.9%, respectively. At week 24, 3 of 6 (50%) patients (JAK inhibitors-treated) achieved TSS50.공시 • Nov 27Jacobio Pharmaceuticals Group Co., Ltd. Completes First Patient Dose in the Phase I/IIa Clinical Trial of Pan-Kras Inhibitor Jab-23E73 in ChinaThe board of directors of JACOBIO PHARMACEUTICALS Group CO., LTD. announced that the Company has completed the first patient dosage in the phase I/IIa clinical trial of its in-house developed pan-KRAS Inhibitor JAB-23E73 in China. KRAS is widely present in a variety of tumor mutations. About 23%-25% of cancer patients have KRAS mutations. About 2.7 million tumor patients with KRAS-related mutations are added each year worldwide and are expected to benefit from pan-KRAS inhibitor. JAB-23E73 can inhibit both the active ("On") and inactive ("Off") states of KRAS and with no obvious inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73's preclinical data has shown a good pharmacokinetic profile.공시 • Oct 09Jacobio Pharmaceuticals Group Co., Ltd. Presents the Pre-Clinical Data of Shp2 Inhibitorjab-3312 in Combination with Kras G12c Inhibitor Glecirasibat the Fifth Ras Initiative Symposium 2024Jacobio Pharmaceuticals Group Co., Ltd. announced that the company presented the pre-clinical data of SHP2 inhibitor JAB-3312 in combo with KRAS G12C inhibitor Glecirasib as form of poster at the Fifth RAS Initiative Symposium 2024. The data showed that Glecirasib and JAB-3312 demonstrate potent anti-tumor effect both in vitro and in vivo, and JAB-3312 enhances the anti-tumor effect of Glecirasib. Representative patient cases were also included in the poster. The clinical data of the combination of JAB-3312 and Glecirasib also verified the above preclinical conclusions. The poster released by Jacobio at 2024 European Society for Medical Oncology (ESMO) Congress (ESMO 2024) showed that the confirmed objective response rate (cORR) of Glecirasib and JAB-3312 as first-line treatment for non-small cell lung cancer (NSCLC) was 70.6% (N=102), and the median progression-free survival (mPFS) remained stable at 12.2 months. Currently, a phase III registration clinical trial of JAB-3312 and Glecirasib for the treatment of first-line NSCLC harboring KRAS G12C mutation has been initiated in China. The Fifth RAS Initiative Symposium was held by Frederick National Laboratory which is affiliated with National Cancer Institute of the United States. Glecirasib (JAB-21822) is a KRAS G12C inhibitor developed by Jacobio. A number of clinical trials of Glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. These include combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with cetuximab in colorectal cancer. The pancreatic cancer indication has obtained orphan drug designation in the United States and breakthrough therapy designation in China. JAB-3312 is a highly selective SHP2 allosteric inhibitor with best-in-class potential. Jacobio is currently conducting clinical trials of JAB-3312 in monotherapy and combination therapies with Glecirasib and other agents in China, the United States and Europe. The phase III study in combination with KRAS G12C inhibitor Glecirasib has been approved by the Center for Drug Evaluation of the National Medical Products Administration of China in February 2024.Reported Earnings • Oct 01First half 2024 earnings released: CN¥0.22 loss per share (vs CN¥0.22 loss in 1H 2023)First half 2024 results: CN¥0.22 loss per share (further deteriorated from CN¥0.22 loss in 1H 2023). Net loss: CN¥169.1m (loss widened 1.7% from 1H 2023). Revenue is expected to decline by 2.4% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 20%.공시 • Sep 23Jacobio Pharmaceuticals Group Co., Ltd. Receives Investigational New Drug (IND) Approval from the U.S. FDA for Pan-KRAS Inhibitor JAB-23E73JACOBIO PHARMACEUTICALS GROUP CO., LTD. announced that, the Food and Drug Administration of the United States has approved the Investigational New Drug application of its self-developed drug JAB-23E73 (Pan-KRAS Inhibitor), and plans to initiate phase I/IIa clinical trial in advanced solid tumor patients. The IND in China has been submitted to the Center for Drug Evaluation of the National Medical Product Administration of the PRC, and the clinical trial in China will be conducted after China IND approval. KRAS is widely present in a variety of tumor mutations. About 23%-25% of cancer patients have KRAS mutations. About 2.7 million tumor patients with KRAS-related mutations are added each year worldwide and are expected to benefit from pan-KRAS inhibitor. JAB-23E73 can inhibit both the active ("On") and inactive ("Off") states of KRAS and with no obvious inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73's preclinical data has showed a good pharmacokinetic profile.공시 • Aug 30Jacobio Pharmaceuticals Group Co., Ltd. Announces Board ChangesJacobio Pharmaceuticals Group Co., Ltd. announced that Ms. Yanmin TANG (" Ms. Tang ") has tendered her resignation from the position as a non-executive Director with effect from August 30, 2024 due to her pursuit of other personal affairs. Accordingly, Ms. Tang will cease to be a member of the nomination committee of the Company (the "Nomination Committee") and the remuneration committee of the Company (the "Remuneration Committee") with effect from August 30, 2024. Ms. Tang confirmed that she The Board further announces that, Dr. Te-li CHEN, a non-executive Director, has been appointed as a member of the Nomination Committee and the Remuneration Committee in place of Ms. Tang with effect from August 30, 2024, respectively.공시 • Aug 20Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024Jacobio Pharmaceuticals Group Co., Ltd. announced that they will report first half, 2024 results on Aug 30, 2024공시 • Aug 07Jacobio Pharmaceuticals Group Co., Ltd. Completes First Patient Dosing in the Phase III Clinical Trial of Glecirasib in Combination with GlecirasibThe board of directors of Jacobio Pharmaceuticals Group Co., Ltd. announced that the Company has completed the first patient dosage in the Phase III clinical trial of KRAS G12C inhibitor Glecirasib in combination with the SHP2 inhibitor JAB-3312 versus standard care (chemotherapy plus anti-PD-1 antibody) in front-line KRAS G12C mutant non-small cell lung cancer (NSCLC). JAB-3312 is the first SHP2 inhibitor that entered a registration clinical trial globally. The new drug application (NDA) of Glecirasib monotherapy for the second-line and beyond NSCLC with KRAS G12C mutation was granted Priority Review designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China on May 21, 2024. According to data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2024, Glecirasib in combined with JAB-3312 resulted confirmed objective response rate (cORR) of 64.7% (66/102) and preliminary median progression-free survival (mPFS) of 12.2 months in the front-line NSCLC. The optimal dosing schedule Glecirasib at 800mg daily combined with JAB-33 12 at 2mg daily one week on and one week off resulted a cORR of 77.4% (24/31), and 54.8% (17/31) of patients achieved a deep response with tumors shrinking by more than 50%. Regarding on the safety data from all study patients the incidence of grade 3 or 4 treatment-related adverse events (TRAE) was 43.8%, and there was no treatment-related death. The overall safety is manageable. Glecirasib (JAB-21822) is a KRAS G12C inhibitor independently developed by Jacobio. A number of Phase I/II clinical trials of Glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. These include a pivotal clinical trial in NSCLC in China, combination therapy trials with SHP2 inhibitor JAB -3312 in NSCLC and with cetuximab in colorectal cancer, and a registrational pivotal clinical trial of single agent for pancreatic cancer. The pancreatic cancer indication has obtained orphan drug designation in the United States and breakthrough therapy designation in China. JAB-3312 is a highly selective SHP2 allosteric inhibitor with the best-in-class potential. Jacobio is currently conducting multiple clinical trials of JAB-3312 in China, the United States, the United States and Europe, including the combination therapy trial with Glecirasib. The Phase III study in combination with KRAS G12C inhibitorlecirasib has been approved in China in February 2024.Board Change • Jun 26Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). Independent Non-Executive Director Bai Lu was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.이익 및 매출 성장 예측DB:77V - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028317N/A-58103212/31/2027268N/A120210212/31/2026724N/A406488212/31/202554-146-213-211N/A9/30/2025127-96-128-124N/A6/30/2025201-46-44-37N/A3/31/2025179-101-65-55N/A12/31/2024156-156-86-74N/A9/30/202489-259-210-199N/A6/30/202423-362-334-325N/A3/31/202443-361-369-345N/A12/31/202364-359-403-364N/A9/30/202372-385-426-382N/A6/30/202381-410-449-400N/A3/31/202389-391-379-346N/A12/31/202296-372-309-292N/A9/30/2022123-332-230-218N/A6/30/2022150-292-151-145N/A3/31/2022151-297-155-146N/A12/31/2021153-301-159-147N/A9/30/2021348-570-70-56N/A6/30/2021544-8391836N/A3/31/2021515-1,1774357N/A12/31/2020486-1,5146879N/A9/30/2020243-1,298-37-30N/A6/30/2020N/A-1,082-141-139N/A3/31/2020N/A-753-129-126N/A12/31/2019N/A-425-116-113N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 77V 의 예상 수익 증가율이 절약률(1.9%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: 77V 의 수익이 German 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: 77V 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: 77V 의 수익(연간 17.7%)이 German 시장(연간 6.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 77V 의 수익(연간 17.7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 77V의 자본 수익률은 3년 후 3.2%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/17 16:43종가2026/06/17 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Jacobio Pharmaceuticals Group Co., Ltd.는 2명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Yu WuCMB International Securities LimitedLinhai ZhaoGoldman Sachs
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Bai Lu was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Mar 11Jacobio Pharmaceuticals Group Co., Ltd., Annual General Meeting, Jun 05, 2026Jacobio Pharmaceuticals Group Co., Ltd., Annual General Meeting, Jun 05, 2026.
공시 • Feb 26Jacobio Pharmaceuticals Group Co., Ltd. to Report Fiscal Year 2025 Results on Mar 10, 2026Jacobio Pharmaceuticals Group Co., Ltd. announced that they will report fiscal year 2025 results on Mar 10, 2026
공시 • Oct 24Jacobio Pharma Presents Pre-Clinical Data of Pan-KRAS Inhibitor (JAB-23E73) at AACR-NCI-EORTC International ConferenceJacobio Pharma announced that it presented the pre-clinical data of its internally discovered pan-KRAS inhibitor JAB-23E73 in a poster presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The pre-clinical results demonstrated that JAB-23E73 is a highly potent pan-KRAS (ON/OFF) inhibitor with strong selectivity that spares HRAS and NRAS inhibition. The compound exhibits superior antitumor activity across multiple cancer types harboring different KRAS driver mutations or amplification. In KRAS-driven mouse tumor models, JAB-23E73 induced tumor regression without causing significant body weight loss, indicating good tolerability and a wide therapeutic window. The compound also showed a favorable pharmacokinetic profile for oral administration and exhibited plasma drug concentration-dependent intratumoral p-ERK inhibition. Phase I clinical trials of JAB-23E73 are currently ongoing in both China and the United States for patients with advanced solid tumors harboring KRAS gene alterations.
공시 • Aug 19Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025Jacobio Pharmaceuticals Group Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025
공시 • Jul 15Jacobio Pharmaceuticals Group Co., Ltd. (SEHK:1167) commences an Equity Buyback for 78,873,528 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2025.Jacobio Pharmaceuticals Group Co., Ltd. (SEHK:1167) commences share repurchases on July 15, 2025, under the program mandated by the shareholders in the Annual General Meeting held on June 10, 2025. As per the mandate, the company is authorized to repurchase up to 78,873,528 shares, representing 10% of its issued share capital. The repurchases will lead to an enhancement of the net asset value per share and/or earnings per share for the company. The repurchases will be made out of the funds legally available for such purpose in accordance with the Articles of Association and the applicable laws of the Cayman Islands and the Listing Rules. The company may cancel such repurchased shares or hold them as treasury shares on or after the Rule Amendment Effective Date. The authority shall expire at the earliest of the next Annual General Meeting, the date on which the next Annual General Meeting is required to be held or the date on which the authority is varied or revoked in a General Meeting. As of June 10, 2025, the company has 791,755,080 shares in issue. On July 14, 2025, the company announces a share repurchase program. Under the program, the company will repurchase up to HKD 100 million worth of its shares. The repurchase price of each share shall be no more than 5% higher than the average closing market price for the shares over the five trading days immediately preceding each repurchase. The company intends to fund the program from its own financial resources.
공시 • Jul 03Jacobio Pharma Submits Phase I/II Investigational New Drug Application for its Bet Inhibitor JAB-8263 for the Treatment of Autoimmune Diseases to the Center for Drug Evaluation in ChinaJacobio Pharma announced that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibitor JAB-8263 for the treatment of autoimmune diseases to the Center for Drug Evaluation (CDE) in China and has been accepted. According to new regulatory guidelines, the review of JAB-8263's IND application is expected to be completed within 30 working days. Previously, Jacobio has completed phase I clinical trials of JAB-8263 for solid tumor and hematological malignancies in both China and the United States. Data presented at the 2024 American Society of Hematology (ASH) Annual Meeting showed that JAB-8263 demonstrated good tolerability.
공시 • Jul 02Jacobio Completes the First Patient Dage in the Phase I/IIa Clinical Trial of Pan-KRAS Inhibitor JAB-23E73 in U.SThe board of directors of JACOBIO PHARMACEUTICALS Group CO., LTD. announced that the Company has completed the first patient dosage in the phase I/IIa clinical trial of its in-house developed pan-KRAS inhibitor JAB-23E73 in U.S. In parallel, the dose-escalation study in China is progressing as planned. KRAS mutations represent one of the most common oncogenic alterations in tumors, occurring in approximately 23%-25% of cancer patients. The mutation frequency is particularly high in pancreatic cancer (90%), colorectal cancer (40%), and non-small cell lung cancer (30%). An estimated 2.7 million newly diagnosed cancer patients worldwide are found to have tumor with KRAS mutations, underscoring the significant unmet need and the potential benefit of pan-KRAS inhibitors for this patient population. JAB-23E73 demonstrates high selectivity for KRAS, effectively inhibiting both the active ("On") and inactive ("Off") states of KRAS, with no inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73 has shown a favorable pharmacokinetic profile and promising anti-tumor activity in preclinical models.
공시 • Mar 20+ 1 more updateJacobio Pharmaceuticals Group Co., Ltd. Announces Board and Composition of the Nomination Committee ChangesThe Board of Jacobio Pharmaceuticals Group Co., Ltd. announced that, Ms. Yunyan HU, an executive Director, has been appointed as a member of the Nomination Committee with effect from March 19, 2025 upon the recommendation of the Nomination Committee. Dr. Te-li CHEN, a non-executive Director, has ceased to be a member of the Nomination Committee with effect from March 19, 2025. Following the above changes, the Nomination Committee comprises Dr. Yinxiang WANG as the chairman, and Ms. Yunyan HU, Dr. Ruilin SONG, Dr. Ge WU and Dr. Bai LU as members.
공시 • Mar 07Jacobio Pharmaceuticals Group Co., Ltd. to Report Fiscal Year 2024 Results on Mar 19, 2025Jacobio Pharmaceuticals Group Co., Ltd. announced that they will report fiscal year 2024 results on Mar 19, 2025
공시 • Jan 07Jacobio Pharma Announces the Registrational Clinical Data of Glecirasib Was Published in Nature MedicineJacobio Pharma announced that the data from a registrational clinical trial of its independently developed KRAS G12C inhibitor glecirasib has been published in Nature Medicine (impact factor 58.7). In the article, Jaocbio disclosed, for the first time, the complete dataset of glecirasib in KRAS G12C mutant non-small cell lung cancer patients in the second line or above setting. The pivotal phase II trial of glecirasib monotherapy demonstrated impressive efficacy, including the confirmed objective response rate of 47.9% (56/117), a median progression-free survival of 8.2 months, and a median overall survival of 13.6 months. Glecirasib has a manageable safety profile. Gleciasib has a favorable gastrointestinal safety profile compared with other KRAS G12C inhibitors. The new drug application of glecirasib is currently under evaluation by the Center for Drug Evaluation of the National Medical Products Administration of China, and has been granted Priority Review Designation.
공시 • Dec 09Jacobio Pharma Presents preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASHJacobio Pharmaceuticals Group Co., Ltd. presented preliminary Phase I data of BET inhibitor JAB-8263 to treat myelofibrosis (MF) at the 2024 ASH (American Society of Hematology) Annual Meeting in San Diego, California. The data showed that JAB-8263 was well tolerated with Recommended Phase 2 Dose (RP2D) being 0.3mg QD. The preliminary efficacy data for JAB-8263 monotherapy in MF are promising, as most patients demonstrated spleen volume reduction (SVR) and total symptom score (TSS) reduction. As of the data cutoff date of October 17, 2024, 16 patients with intermediate-/high-risk MF have been enrolled, and 13 patients have undergone at least one post-treatment efficacy assessment. All patients showed a mean SVR-19.95% at week 24 and -26.16% at best response. Two patients achieved =35% SVR, and an SVR of -34.9% was observed in one patient. Six of ten (60%) patients experienced a =50% reduction in TSS at week 24. The best response of SVR in 2 of 8 patients (JAK inhibitors-treated) was -41.2% and -34.9%, respectively. At week 24, 3 of 6 (50%) patients (JAK inhibitors-treated) achieved TSS50.
공시 • Nov 27Jacobio Pharmaceuticals Group Co., Ltd. Completes First Patient Dose in the Phase I/IIa Clinical Trial of Pan-Kras Inhibitor Jab-23E73 in ChinaThe board of directors of JACOBIO PHARMACEUTICALS Group CO., LTD. announced that the Company has completed the first patient dosage in the phase I/IIa clinical trial of its in-house developed pan-KRAS Inhibitor JAB-23E73 in China. KRAS is widely present in a variety of tumor mutations. About 23%-25% of cancer patients have KRAS mutations. About 2.7 million tumor patients with KRAS-related mutations are added each year worldwide and are expected to benefit from pan-KRAS inhibitor. JAB-23E73 can inhibit both the active ("On") and inactive ("Off") states of KRAS and with no obvious inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73's preclinical data has shown a good pharmacokinetic profile.
공시 • Oct 09Jacobio Pharmaceuticals Group Co., Ltd. Presents the Pre-Clinical Data of Shp2 Inhibitorjab-3312 in Combination with Kras G12c Inhibitor Glecirasibat the Fifth Ras Initiative Symposium 2024Jacobio Pharmaceuticals Group Co., Ltd. announced that the company presented the pre-clinical data of SHP2 inhibitor JAB-3312 in combo with KRAS G12C inhibitor Glecirasib as form of poster at the Fifth RAS Initiative Symposium 2024. The data showed that Glecirasib and JAB-3312 demonstrate potent anti-tumor effect both in vitro and in vivo, and JAB-3312 enhances the anti-tumor effect of Glecirasib. Representative patient cases were also included in the poster. The clinical data of the combination of JAB-3312 and Glecirasib also verified the above preclinical conclusions. The poster released by Jacobio at 2024 European Society for Medical Oncology (ESMO) Congress (ESMO 2024) showed that the confirmed objective response rate (cORR) of Glecirasib and JAB-3312 as first-line treatment for non-small cell lung cancer (NSCLC) was 70.6% (N=102), and the median progression-free survival (mPFS) remained stable at 12.2 months. Currently, a phase III registration clinical trial of JAB-3312 and Glecirasib for the treatment of first-line NSCLC harboring KRAS G12C mutation has been initiated in China. The Fifth RAS Initiative Symposium was held by Frederick National Laboratory which is affiliated with National Cancer Institute of the United States. Glecirasib (JAB-21822) is a KRAS G12C inhibitor developed by Jacobio. A number of clinical trials of Glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. These include combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with cetuximab in colorectal cancer. The pancreatic cancer indication has obtained orphan drug designation in the United States and breakthrough therapy designation in China. JAB-3312 is a highly selective SHP2 allosteric inhibitor with best-in-class potential. Jacobio is currently conducting clinical trials of JAB-3312 in monotherapy and combination therapies with Glecirasib and other agents in China, the United States and Europe. The phase III study in combination with KRAS G12C inhibitor Glecirasib has been approved by the Center for Drug Evaluation of the National Medical Products Administration of China in February 2024.
Reported Earnings • Oct 01First half 2024 earnings released: CN¥0.22 loss per share (vs CN¥0.22 loss in 1H 2023)First half 2024 results: CN¥0.22 loss per share (further deteriorated from CN¥0.22 loss in 1H 2023). Net loss: CN¥169.1m (loss widened 1.7% from 1H 2023). Revenue is expected to decline by 2.4% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 20%.
공시 • Sep 23Jacobio Pharmaceuticals Group Co., Ltd. Receives Investigational New Drug (IND) Approval from the U.S. FDA for Pan-KRAS Inhibitor JAB-23E73JACOBIO PHARMACEUTICALS GROUP CO., LTD. announced that, the Food and Drug Administration of the United States has approved the Investigational New Drug application of its self-developed drug JAB-23E73 (Pan-KRAS Inhibitor), and plans to initiate phase I/IIa clinical trial in advanced solid tumor patients. The IND in China has been submitted to the Center for Drug Evaluation of the National Medical Product Administration of the PRC, and the clinical trial in China will be conducted after China IND approval. KRAS is widely present in a variety of tumor mutations. About 23%-25% of cancer patients have KRAS mutations. About 2.7 million tumor patients with KRAS-related mutations are added each year worldwide and are expected to benefit from pan-KRAS inhibitor. JAB-23E73 can inhibit both the active ("On") and inactive ("Off") states of KRAS and with no obvious inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73's preclinical data has showed a good pharmacokinetic profile.
공시 • Aug 30Jacobio Pharmaceuticals Group Co., Ltd. Announces Board ChangesJacobio Pharmaceuticals Group Co., Ltd. announced that Ms. Yanmin TANG (" Ms. Tang ") has tendered her resignation from the position as a non-executive Director with effect from August 30, 2024 due to her pursuit of other personal affairs. Accordingly, Ms. Tang will cease to be a member of the nomination committee of the Company (the "Nomination Committee") and the remuneration committee of the Company (the "Remuneration Committee") with effect from August 30, 2024. Ms. Tang confirmed that she The Board further announces that, Dr. Te-li CHEN, a non-executive Director, has been appointed as a member of the Nomination Committee and the Remuneration Committee in place of Ms. Tang with effect from August 30, 2024, respectively.
공시 • Aug 20Jacobio Pharmaceuticals Group Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024Jacobio Pharmaceuticals Group Co., Ltd. announced that they will report first half, 2024 results on Aug 30, 2024
공시 • Aug 07Jacobio Pharmaceuticals Group Co., Ltd. Completes First Patient Dosing in the Phase III Clinical Trial of Glecirasib in Combination with GlecirasibThe board of directors of Jacobio Pharmaceuticals Group Co., Ltd. announced that the Company has completed the first patient dosage in the Phase III clinical trial of KRAS G12C inhibitor Glecirasib in combination with the SHP2 inhibitor JAB-3312 versus standard care (chemotherapy plus anti-PD-1 antibody) in front-line KRAS G12C mutant non-small cell lung cancer (NSCLC). JAB-3312 is the first SHP2 inhibitor that entered a registration clinical trial globally. The new drug application (NDA) of Glecirasib monotherapy for the second-line and beyond NSCLC with KRAS G12C mutation was granted Priority Review designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China on May 21, 2024. According to data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2024, Glecirasib in combined with JAB-3312 resulted confirmed objective response rate (cORR) of 64.7% (66/102) and preliminary median progression-free survival (mPFS) of 12.2 months in the front-line NSCLC. The optimal dosing schedule Glecirasib at 800mg daily combined with JAB-33 12 at 2mg daily one week on and one week off resulted a cORR of 77.4% (24/31), and 54.8% (17/31) of patients achieved a deep response with tumors shrinking by more than 50%. Regarding on the safety data from all study patients the incidence of grade 3 or 4 treatment-related adverse events (TRAE) was 43.8%, and there was no treatment-related death. The overall safety is manageable. Glecirasib (JAB-21822) is a KRAS G12C inhibitor independently developed by Jacobio. A number of Phase I/II clinical trials of Glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. These include a pivotal clinical trial in NSCLC in China, combination therapy trials with SHP2 inhibitor JAB -3312 in NSCLC and with cetuximab in colorectal cancer, and a registrational pivotal clinical trial of single agent for pancreatic cancer. The pancreatic cancer indication has obtained orphan drug designation in the United States and breakthrough therapy designation in China. JAB-3312 is a highly selective SHP2 allosteric inhibitor with the best-in-class potential. Jacobio is currently conducting multiple clinical trials of JAB-3312 in China, the United States, the United States and Europe, including the combination therapy trial with Glecirasib. The Phase III study in combination with KRAS G12C inhibitorlecirasib has been approved in China in February 2024.
Board Change • Jun 26Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). Independent Non-Executive Director Bai Lu was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.